Altreno is a drug owned by Dow Pharmaceutical Sciences. It is protected by 3 US drug patents filed from 2019 to 2022. Out of these, 2 drug patents are active and 1 has expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 22, 2038. Details of Altreno's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10653656 | Topical pharmaceutical compositions for treating skin conditions |
Aug, 2038
(12 years from now) | Active |
| US11324710 | Topical pharmaceutical compositions for treating skin conditions |
Aug, 2038
(12 years from now) | Active |
| US6517847 | Topical gel delivery system |
Aug, 2020
(5 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Altreno's patents.
Latest Legal Activities on Altreno's Patents
Given below is the list of recent legal activities going on the following patents of Altreno.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Oct, 2023 | US10653656 |
| Recordation of Patent Grant Mailed
Critical | 10 May, 2022 | US11324710 |
| Patent Issue Date Used in PTA Calculation
Critical | 10 May, 2022 | US11324710 |
| Email Notification
Critical | 21 Apr, 2022 | US11324710 |
| Issue Notification Mailed
Critical | 20 Apr, 2022 | US11324710 |
| Dispatch to FDC | 06 Apr, 2022 | US11324710 |
| Application Is Considered Ready for Issue
Critical | 06 Apr, 2022 | US11324710 |
| Issue Fee Payment Verified
Critical | 05 Apr, 2022 | US11324710 |
| Issue Fee Payment Received
Critical | 05 Apr, 2022 | US11324710 |
| Email Notification
Critical | 22 Mar, 2022 | US11324710 |
FDA has granted several exclusivities to Altreno. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Altreno, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Altreno.
Exclusivity Information
Altreno holds 1 exclusivities. All of its exclusivities have expired in 2021. Details of Altreno's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Aug 23, 2021 |
US patents provide insights into the exclusivity only within the United States, but
Altreno is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Altreno's family patents as well as insights into
ongoing legal events
on those patents.
Altreno's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Altreno's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Aug 22, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Altreno Generic API suppliers:
Tretinoin is the generic name for the brand Altreno. 15 different companies have already filed for the generic of Altreno, with Padagis Us having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Altreno's generic
Alternative Brands for Altreno
Altreno which is used for treating acne vulgaris in patients 9 years of age and older., has several other brand drugs in the same treatment category and using the same active ingredient (Tretinoin). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Bausch |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Tretinoin. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Advanz Pharma |
| |||
| Almirall |
| |||
| Bausch |
| |||
| Dow Pharm |
| |||
| Galderma Labs Lp |
| |||
| Mayne Pharma |
| |||
| Sun Pharm |
| |||
| Sun Pharm Inds Inc |
| |||
| Valeant Pharms North |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Tretinoin, Altreno's active ingredient. Check the complete list of approved generic manufacturers for Altreno
About Altreno
Altreno is a drug owned by Dow Pharmaceutical Sciences. It is used for treating acne vulgaris in patients 9 years of age and older. Altreno uses Tretinoin as an active ingredient. Altreno was launched by Dow Pharm in 2018.
Approval Date:
Altreno was approved by FDA for market use on 23 August, 2018.
Active Ingredient:
Altreno uses Tretinoin as the active ingredient. Check out other Drugs and Companies using Tretinoin ingredient
Treatment:
Altreno is used for treating acne vulgaris in patients 9 years of age and older.
Dosage:
Altreno is available in lotion form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.05% | LOTION | Prescription | TOPICAL |